Crown Laboratories Acquires Revance Therapeutics

Crown Aesthetics (Crown Laboratories) Acquires Select Assets from Healeon LLC (Bimini Health Tech)

July 23, 2024

Medical Devices

Crown Aesthetics, a Crown Laboratories company, has acquired select assets and technology from Healeon LLC, a subsidiary of Bimini Health Tech, to strengthen its ProGen PRP Eclipse platelet-rich plasma (PRP) offering. The asset purchase expands Crown's PRP device portfolio, supports new product development, and aims to extend Crown's geographic and production capabilities in the regenerative and aesthetic medicine markets.

Crown Laboratories Acquires StriVectin from L Catterton

August 26, 2021

Consumer Products

Crown Laboratories, a Hildred Capital portfolio company, has entered into a definitive agreement to acquire StriVectin from L Catterton. StriVectin will operate as a wholly owned subsidiary within Crown's new Premium Skincare Division, with its president Cori Aleardi joining Crown's executive team; the deal was expected to close by mid-September 2021.

Validant Acquires DataRevive

November 1, 2019

Healthcare Services

Validant, a transatlantic quality, compliance and regulatory consulting group backed by GHO Capital, has acquired DataRevive, a regulatory strategy and consulting firm focused on novel therapeutics and biologics. The deal expands Validant's capabilities in life‑science regulatory consulting and adds a Washington, D.C. location to its existing footprint in San Francisco, Research Triangle Park and Cork, Ireland.

Crown Laboratories Acquires Eclipse Medcorp's Aesthetics Assets

May 24, 2022

Medical Devices

Crown Laboratories has acquired the global, aesthetics-focused assets of Eclipse Medcorp, LLC, expanding Crown's aesthetics product portfolio and integrating Eclipse's devices into its Aesthetics business unit. The deal aims to broaden Crown's product offerings to aesthetics providers domestically and internationally and preserve service and medical-education support for Eclipse customers under Crown.

Revive Therapeutics Agrees to Acquire Psilocin Pharma Corp.

February 11, 2020

Pharmaceuticals

Revive Therapeutics Ltd. entered into a letter of intent to acquire all issued and outstanding securities of Psilocin Pharma Corp. for an aggregate purchase price of $2.75 million to be satisfied by issuing 55 million common shares of Revive (deemed $0.05/share). Revive deposited 10 million shares ($500,000) into escrow as a deposit; the closing is subject to due diligence and execution of a definitive share exchange agreement.

Revive Infrastructure Group Acquires Crown Utilities

December 6, 2021

Construction

Revive Infrastructure Group, in partnership with Sileo Capital and Brightwood Capital, acquired Crown Utilities, a Nampa, Idaho-based utility contractor focused on telecommunications infrastructure. The deal expands Revive's capabilities and geographic footprint in the Intermountain West; Crown will retain its brand and Ken Killingbeck will continue as president.